6322 related articles for article (PubMed ID: 3558118)
21. XB596, a promising bis-naphthalimide anti-cancer agent.
Chen SF; Behrens DL; Behrens CH; Czerniak PM; Dexter DL; Dusak BL; Fredericks JR; Gale KC; Gross JL; Jiang JB
Anticancer Drugs; 1993 Aug; 4(4):447-57. PubMed ID: 8400347
[TBL] [Abstract][Full Text] [Related]
22. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.
Neil GL; Kuentzel SL; McGovren JP
Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
Fujimoto S; Wang Y; Inoue K; Ogawa M
Jpn J Cancer Res; 1985 Jul; 76(7):644-50. PubMed ID: 3161854
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.
Leopold WR; Shillis JL; Mertus AE; Nelson JM; Roberts BJ; Jackson RC
Cancer Res; 1984 May; 44(5):1928-32. PubMed ID: 6546897
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo anti-tumor activity of L-glutamic acid gamma-monohydroxamate against L1210 leukemia and B16 melanoma.
Vila J; Thomasset N; Navarro C; Doré JF
Int J Cancer; 1990 Apr; 45(4):737-43. PubMed ID: 2323850
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of newly isolated antibiotics, 3-dichloromethylactinobolins.
Okumoto T; Kontani M; Hoshino H; Nakanishi M
J Pharmacobiodyn; 1980 Mar; 3(3):177-82. PubMed ID: 7205539
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
Lasek W; Giermasz A; Kuc K; Wańkowicz A; Feleszko W; Gołab J; Zagozdzon R; Stokłosa T; Jakóbisiak M
Int J Cancer; 1996 May; 66(3):374-9. PubMed ID: 8621260
[TBL] [Abstract][Full Text] [Related]
28. Some chemotherapeutic properties of two new antitumor antibiotics, saframycins A and C.
Arai T; Takahashi K; Ishiguro K; Mikami Y
Gan; 1980 Dec; 71(6):790-6. PubMed ID: 7274625
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and antitumor activity of isodoxorubicin analogues.
Florent JC; Gaudel G; Monneret C; Hoffmann D; Kraemer HP
J Med Chem; 1993 May; 36(10):1364-8. PubMed ID: 8496904
[TBL] [Abstract][Full Text] [Related]
30. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.
Chlebowski RT; Dietrich M; Akman S; Block JB
Cancer Treat Rep; 1985 May; 69(5):527-32. PubMed ID: 4005875
[TBL] [Abstract][Full Text] [Related]
31. A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Atassi G; Dumont P; Kabbe HJ; Yoder O
Drugs Exp Clin Res; 1988; 14(9):571-4. PubMed ID: 3229319
[TBL] [Abstract][Full Text] [Related]
32. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
33. Hydramycin, a new antitumor antibiotic. Taxonomy, isolation, physico-chemical properties, structure and biological activity.
Hanada M; Kaneta K; Nishiyama Y; Hoshino Y; Konishi M; Oki T
J Antibiot (Tokyo); 1991 Aug; 44(8):824-31. PubMed ID: 1833366
[TBL] [Abstract][Full Text] [Related]
34. In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
Jurd L; Narayanan VL; Paull KD
J Med Chem; 1987 Oct; 30(10):1752-6. PubMed ID: 2821258
[TBL] [Abstract][Full Text] [Related]
35. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
[TBL] [Abstract][Full Text] [Related]
37. Modification of transplantability and tumor growth following treatment of L1210 leukemia and TA3Ha cells with macromomycin (NSC-170105).
Lippman MM; Abbott BJ
Cancer Chemother Rep; 1973; 57(4):501-3. PubMed ID: 4762442
[No Abstract] [Full Text] [Related]
38. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
39. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
[TBL] [Abstract][Full Text] [Related]
40. Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
Sengupta SK; Rosenbaum DP; Sehgal RK; Almassian B; Blondin J
J Med Chem; 1988 Aug; 31(8):1540-7. PubMed ID: 3397991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
